Pfizer Studies Israel’s Coronavirus Vaccination Campaign

Israel’s fast vaccination effort is providing important information about drug company Pfizer’s COVID-19 vaccine.

Reporters with the Reuters news agency spoke to leading scientists in Israel and other places, Israeli health officials, hospital heads and two of the country’s largest healthcare providers. The aim was to find the latest information about the country’s especially fast vaccination campaign.

About 3.5 million Israelis have been fully or partly vaccinated. That is more than half of people who are in groups that are supposed to be vaccinated first. These groups are showing a sharp drop in infections.

Eran Segal is a data scientist at the Weizmann Institute of Science in Rehovot, Israel. He said there was a 53 percent reduction in new cases in the first fully vaccinated group. In addition, there were 39 percent fewer hospitalizations and a 31 percent drop in severe illnesses from the middle of January until February 6, Segal said.

More information will be known in two weeks, as teams study the vaccine’s effectiveness in younger groups of Israelis and people with certain conditions.

“We need to have enough variety of people in that subgroup and enough follow-up time so you can make the right conclusions, and we are getting to that point,” said Ran Balicer. He is an official with the Israeli health services provider Clalit.

Pfizer is watching the Israeli effort each week to understand more about the vaccine and how it is working.

Israel’s campaign provides Pfizer and its partner, Germany’s BioNTech, with an unusual chance. The small country has healthcare for all its citizens, and the ability to gather and study data. Israel also has quickly provided the vaccine to its citizens.

Israel still faces struggles in its effort to fight the virus. The country’s third national lockdown has not slowed the spread of COVID-19. A fast-spreading variant of the virus that was first found in Britain is now spreading in Israel. So far, the Pfizer/BioNTech shot appears to be effective against it.

“We’ve so far identified the same 90 percent to 95 percent efficacy against the British strain,” said Hezi Levi. He is a director-general of the Israeli Health Ministry.

The Pfizer vaccine requires two doses, or shots, to be effective. For this reason, Levi said it is too early to know about levels of protection because many people only received the second dose in the last week. He added that it is still too early to know whether the vaccine is effective against another fast-spreading virus variant that began in South Africa.